Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04472598
Other study ID # M16-191
Secondary ID 2020-000097-15
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 29, 2020
Est. completion date October 19, 2032

Study information

Verified date March 2024
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases risk of bleeding. Myelofibrosis often causes an enlarged spleen. The purpose of this study is to see if a combination of navitoclax and ruxolitinib is more effective and safe in assessment of change in spleen volume when compared to ruxolitinib in participants with myelofibrosis. Navitoclax is an investigational drug for the treatment of myelofibrosis. Participants in this study are divided into two groups, called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of myelofibrosis will be enrolled. Around 230 participants will be enrolled in approximately 190 sites worldwide. Participants will receive oral navitoclax tablet with oral ruxolitinib tablet or oral ruxolitinib tablet with oral placebo (no active drug) tablet and treatment may continue untill the participant cannot tolerate the study drug, or benefit is not achieved, or other reasons which qualify for discontinuation of the study drug. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, magnetic resonance imaging (MRI) or computed tomography (CT) scan, bone marrow tests, checking for side effects, and completing questionnaires.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 252
Est. completion date October 19, 2032
Est. primary completion date April 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Documented diagnosis of Primary MyeloFibrosis (MF) as defined by World Health Organization (WHO) classification or Secondary MF (post polycythemia vera [PPV] - MF or Post Essential Thrombocytopenia [PET] - MF) . - Must be able to complete the MF Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of 7 days immediately preceding the date of randomization. -- Must have at least 2 symptoms with a score >=3 or a total score of >=12, as measured by the MFSAF v4.0. - Classified as intermediate-2, or high-Risk MF as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+). - Has splenomegaly defined as spleen palpation measurement >= 5 centimeters (cm) below costal margin or spleen volume greater than or equal to 450 cubic cm as assessed centrally by magnetic resonance imaging (MRI) or computed tomography (CT) scan. - Ineligible for stem cell transplantation at time of study entry due to age, comorbidities, or unfit for unrelated or unmatched donor transplant and other criteria per National Comprehensive Cancer Network guidelines. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Exclusion Criteria: - Prior treatment with a Janus Kinase-2 (JAK-2) inhibitor. - Prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound or bromodomain and extra-terminal motif (BET) inhibitor or stem cell transplant. - Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period except for low dose aspirin (up to 100 milligram daily) and low molecular weight heparin (LMWH).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Navitoclax
Tablet; Oral
Ruxolitinib
Tablet; Oral
Placebo for Navitoclax
Tablet; Oral

Locations

Country Name City State
Australia The Kinghorn Cancer Centre /ID# 221503 Darlinghurst New South Wales
Australia Townsville University Hospital /ID# 229794 Douglas Queensland
Australia Border Medical Oncology Research Unit Albury Wodonga Regional Cancer Centre /ID# 231311 East Albury New South Wales
Australia Gosford Hospital /ID# 221499 Gosford New South Wales
Australia Liverpool Hospital /ID# 221803 Liverpool New South Wales
Australia Alfred Health /ID# 221501 Melbourne Victoria
Australia Peter MacCallum Cancer Ctr /ID# 229795 Melbourne Victoria
Australia Royal Perth Hospital /ID# 223203 Perth Western Australia
Austria Medizinische Universitaet Graz /ID# 220910 Graz Steiermark
Austria Ordensklinikum Linz GmbH Elisabethinen /ID# 220813 Linz Oberoesterreich
Austria Medizinische Universitaet Wien /ID# 220906 Vienna Wien
Austria Klinikum Wels-Grieskirchen GmbH /ID# 220901 Wels Oberoesterreich
Austria Hanusch Krankenhaus /ID# 220909 Wien
Belgium ZNA Stuivenberg /ID# 221465 Antwerp
Belgium AZ Sint-Jan Brugge /ID# 218805 Brugge
Belgium UZ Gent /ID# 221125 Gent Oost-Vlaanderen
Belgium CHU UCL Namur - site Godinne /ID# 221127 Godinne Namur
Belgium Universitair Ziekenhuis Leuven /ID# 218806 Leuven Vlaams-Brabant
Belgium Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 218874 Liege
Belgium AZ-Delta /ID# 221466 Roeselare West-Vlaanderen
Belgium Vitaz /Id# 229861 Sint-Niklaas
Bulgaria UMHAT Dr Georgi Stranski EAD /ID# 231161 Pleven
Bulgaria UMHAT Sveti Georgi /ID# 231053 Plovdiv
Bulgaria Acibadem City Clinic Tokuda University Hospital EAD /ID# 231036 Sofia
Bulgaria UMHAT Sveti Ivan Rilski /ID# 231028 Sofia
Bulgaria UMHAT Alexandrovska EAD /ID# 231056 Sofiya Sofia
Canada Royal Victoria Hospital /ID# 222636 Barrie Ontario
Canada Juravinski Cancer Centre /ID# 221752 Hamilton Ontario
Canada Lakeridge Health - Oshawa /ID# 222080 Oshawa Ontario
Canada CHUQ- Hôpital de l'Enfant-Jesus /ID# 221754 Quebec City Quebec
Canada Niagara Health System /ID# 230994 St Catharines Ontario
Croatia Klinicki bolnicki centar Split /ID# 230796 Split Splitsko-dalmatinska Zupanija
Croatia Clinical Hospital Dubrava /ID# 230795 Zagreb Grad Zagreb
Croatia Klinicka bolnica Merkur /ID# 231155 Zagreb Grad Zagreb
Croatia Klinicki bolnicki centar Zagreb /ID# 230793 Zagreb Grad Zagreb
France Chu Angers /Id# 219115 Angers
France Hopital Avicenne - APHP /ID# 221286 Bobigny Ile-de-France
France Centre Hospitalier de CHAMBERY /ID# 224506 Chambery Savoie
France CHU de Nantes, Hotel Dieu -HME /ID# 219113 Nantes Pays-de-la-Loire
France CHU NIMES - Hopital Caremeau /ID# 219114 Nimes CEDEX 9 Gard
France AP-HP - Hopital Necker /ID# 231318 Paris
France AP-HP - Hopital Saint-Louis /ID# 221288 Paris
France CHU Bordeaux - Hopital Haut Leveque /ID# 222518 Pessac Gironde
France HCL - Hopital Lyon Sud /ID# 222913 Pierre Benite CEDEX Auvergne-Rhone-Alpes
France CH Roubaix - Hopital Victor Provo /ID# 219116 Roubaix Cedex 1 Hauts-de-France
France ICANS - Institut de Cancérologie Strasbourg Europe /ID# 229978 Strasbourg Cedex
Germany Universitaetsklinikum Aachen /ID# 221519 Aachen Nordrhein-Westfalen
Germany BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 221347 Dresden Sachsen
Germany Universitaetsklinikum Essen /ID# 221522 Essen
Germany OncoResearch Lerchenfeld GmbH /ID# 230867 Hamburg
Germany Universitatsklinikum Mannheim /ID# 221523 Mannheim Baden-Wuerttemberg
Germany Haemato-Onkologie /ID# 221061 Muenchen Bayern
Germany Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 221520 Munich
Greece General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 230786 Athens
Greece General Hospital of Athens Laiko /ID# 230785 Athens Attiki
Greece University General Hospital Attikon /ID# 230784 Athens Attiki
Israel Assaf Harofeh Medical Center /ID# 222957 Be'Er Ya'Akov
Israel Rambam Health Care Campus /ID# 219120 Haifa
Israel Hadassah Medical Center-Hebrew University /ID# 219110 Jerusalem Yerushalayim
Israel Meir Medical Center /ID# 221374 Kfar Saba
Israel The Chaim Sheba Medical Center /ID# 219137 Ramat Gan Tel-Aviv
Israel Tel Aviv Sourasky Medical Center /ID# 219134 Tel Aviv-Yafo Tel-Aviv
Italy Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni /ID# 221907 Bergamo
Italy IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 220867 Bologna
Italy ASST Spedali civili di Brescia /ID# 241273 Brescia
Italy A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 219085 Catania
Italy Azienda Ospedaliero Universitaria Careggi /ID# 219086 Florence
Italy Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 219083 Rome Lazio
Italy ASST Sette Laghi /ID# 219084 Varese
Japan Juntendo University Hospital /ID# 221405 Bunkyo-ku Tokyo
Japan Nippon Medical School Hospital /ID# 221674 Bunkyo-ku Tokyo
Japan Chiba University Hospital /ID# 239345 Chiba-shi Chiba
Japan University of Yamanashi Hospital /ID# 221701 Chuo-shi Yamanashi
Japan Kyushu University Hospital /ID# 221783 Fukuoka-shi Fukuoka
Japan Fukushima Medical University Hospital /ID# 222752 Fukushima-shi Fukushima
Japan Kansai Medical University Hospital /ID# 221482 Hirakata-shi Osaka
Japan Hitachi General Hospital /ID# 240048 Hitachi-shi Ibaraki
Japan Juntendo University Shizuoka Hospital /ID# 221782 Izunokuni-shi Shizuoka
Japan Kanazawa University Hospital /ID# 238424 Kanazawa-shi Ishikawa
Japan Medical Corporation Seijinkai Ikeda Hospital /ID# 242172 Kanoya-shi Kagoshima
Japan National Cancer Center Hospital East /ID# 226093 Kashiwa-shi Chiba
Japan Kobe University Hospital /ID# 246236 Kobe-shi Hyogo
Japan Dokkyo Medical University Saitama Medical Center /ID# 222333 Koshigaya-shi Saitama
Japan Kawasaki Medical School Hospital /ID# 221481 Kurashiki-shi Okayama
Japan Kurashiki Central Hospital /ID# 221692 Kurashiki-shi Okayama
Japan Kyoto University Hospital /ID# 238423 Kyoto-shi Kyoto
Japan Gunma University Hospital /ID# 221480 Maebashi-shi Gunma
Japan Gunmaken Saiseikai Maebashi Hospital /ID# 242806 Maebashi-shi Gunma
Japan University of Miyazaki Hospital /ID# 221483 Miyazaki-shi Miyazaki
Japan Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 239100 Nagoya-shi Aichi
Japan Ogaki Municipal Hospital /ID# 240173 Ogaki-shi Gifu
Japan Kindai University Hospital /ID# 221479 Osakasayama-shi Osaka
Japan Hokkaido University Hospital /ID# 242667 Sapporo-shi Hokkaido
Japan Osaka University Hospital /ID# 221478 Suita-shi Osaka
Japan Ehime University Hospital /ID# 221443 Toon-shi Ehime
Japan Fujita Health University Hospital /ID# 221537 Toyoake-shi Aichi
Japan Mie University Hospital /ID# 221664 Tsu-shi Mie
Korea, Republic of Inje University Busan Paik Hospital /ID# 231667 Busan
Korea, Republic of Pusan National University Hospital /ID# 222087 Busan
Korea, Republic of Kyungpook National University Hospital /ID# 231666 Daegu
Korea, Republic of Gachon University Gil Medical Center /ID# 222089 Incheon
Korea, Republic of Seoul National University Bundang Hospital /ID# 219053 Seongnam Gyeonggido
Korea, Republic of Asan Medical Center /ID# 219054 Seoul
Korea, Republic of Samsung Medical Center /ID# 221068 Seoul
Korea, Republic of Seoul National University Hospital /ID# 219055 Seoul
Korea, Republic of The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 219056 Seoul
Netherlands Albert Schweitzer Ziekenhuis /ID# 224015 Dordrecht Zuid-Holland
Netherlands Universitair Medisch Centrum Groningen /ID# 218947 Groningen
Netherlands Radboud Universitair Medisch Centrum /ID# 218948 Nijmegen Gelderland
Netherlands Universitair Medisch Centrum Utrecht /ID# 218949 Utrecht
New Zealand Middlemore Clinical Trials /ID# 230770 Papatoetoe Auckland
Russian Federation Moscow State budget healthcare /ID# 221025 Moscow Moskva
Russian Federation Republican hospital named after V.A. Baranov /ID# 221412 Petrozavodsk
Russian Federation Clinic UZI 4D /ID# 221024 Pyatigorsk Stavropol Skiy Kray
Russian Federation Leningrad Regional Clinical Hospital /ID# 221028 Saint Petersburg
Russian Federation Almazov National Medical Research Centre /ID# 221033 Sankt-Peterburg
Russian Federation Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 221029 Sankt-Peterburg
Russian Federation Tula Regional Clinical Hospital /ID# 221027 Tula
Serbia Clin Hosp Ctr Bezanijska Kosa /ID# 230946 Belgrade Beograd
Serbia University Clinical Center Serbia /ID# 230854 Belgrade Beograd
Serbia University Clinical Center Kragujevac /ID# 230855 Kragujevac Sumadijski Okrug
Serbia Clinical Center Vojvodina /ID# 230853 Novi Sad Vojvodina
South Africa Wits Clinical Research Site /ID# 232071 Johannesburg Gauteng
South Africa Wits Clinical Research Site /ID# 232072 Johannesburg Gauteng
South Africa Albert Alberts Stem Cell Transplant Centre /ID# 232073 Pretoria Gauteng
Spain Hospital Universitario Germans Trias i Pujol /ID# 229936 Badalona Barcelona
Spain Hospital Parc de Salut del Mar /ID# 220913 Barcelona
Spain Hospital Universitario Vall d'Hebron /ID# 229690 Barcelona
Spain Hospital Universitario Dr. Negrin /ID# 220897 Las Palmas de Gran Canaria Las Palmas
Spain CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 230721 Madrid
Spain Hospital Universitario 12 de Octubre /ID# 229691 Madrid
Spain Hospital Universitario Ramon y Cajal /ID# 220877 Madrid
Spain Hospital Universitario Virgen de la Victoria /ID# 220878 Malaga
Spain CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 230720 Pamplona Navarra
Spain Hospital Clínico Universitario de Santiago-CHUS /ID# 222264 Santiago de Compostela A Coruna
Spain Hospital Clinico Universitario de Valencia /ID# 220875 Valencia
Sweden Sahlgrenska University Hospital /ID# 218776 Gothenburg Vastra Gotalands Lan
Sweden Skane University Hospital Lund /ID# 220835 Lund Skane Lan
Sweden Orebro Universitetssjukhuset /ID# 220829 Orebro Orebro Lan
Taiwan Kaohsiung Chang Gung Memorial Hospital /ID# 218984 Kaohsiung City Kaohsiung
Taiwan China Medical University Hospital /ID# 218978 Taichung City
Taiwan Chi Mei Hospital - Liouying /ID# 221145 Tainan City
Taiwan National Taiwan University Hospital /ID# 218976 Taipei City
Taiwan Taipei Veterans General Hosp /ID# 221146 Taipei City
Taiwan Linkou Chang Gung Memorial Hospital /ID# 218983 Taoyuan City
Turkey Hacettepe University Medical Faculty /ID# 230759 Ankara
Turkey Trakya University Medical Facu /ID# 230754 Edirne, Istanbul
Turkey Bagcilar Medipol Mega Universite Hastanesi /ID# 230757 Istanbul
Turkey Ege University Medical Faculty /ID# 230753 Izmir
Turkey Inonu University Medical Faculty /ID# 230758 Malatya
Ukraine Communal non-profit enterprise Regional Center of Oncology /ID# 230832 Kharkiv
Ukraine Feofaniya Clinical Hospital of State Management of Affairs /ID# 232370 Kyiv
Ukraine Medical Center "OK!Clinic+" /ID# 230834 Kyiv
Ukraine SI Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine /ID# 230833 Lviv
United Kingdom University Hospitals Birmingham NHS Foundation Trust /ID# 221333 Birmingham
United Kingdom United Lincolnshire Hospitals NHS Trust /ID# 231471 Lincoln Lincolnshire
United Kingdom Guys and St Thomas NHS Foundation Trust /ID# 219185 London London, City Of
United Kingdom The Christie Hospital /ID# 219191 Manchester
United Kingdom Oxford University Hospitals NHS Foundation Trust /ID# 219192 Oxford Oxfordshire
United States University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 221658 Ann Arbor Michigan
United States Emory University /ID# 221562 Atlanta Georgia
United States Augusta University Georgia Cancer Center /ID# 221551 Augusta Georgia
United States Lynn Cancer Institute, Boca /ID# 230687 Boca Raton Florida
United States Beth Israel Deaconess Medical Center /ID# 224261 Boston Massachusetts
United States Dana-Farber Cancer Institute /ID# 218010 Boston Massachusetts
United States Massachusetts General Hospital /ID# 221559 Boston Massachusetts
United States Gabrail Cancer Center Research /ID# 230488 Canton Ohio
United States Rush University Medical Center /ID# 221581 Chicago Illinois
United States Oncology Hematology Care, Inc. /ID# 222556 Cincinnati Ohio
United States Columbus Regional Research Institute /ID# 227272 Columbus Georgia
United States The Ohio State University /ID# 221584 Columbus Ohio
United States Minnesota Oncology Hematology /ID# 227357 Edina Minnesota
United States Virginia Cancer Specialists - Fairfax /ID# 242682 Fairfax Virginia
United States University of Kansas Cancer Center /ID# 218144 Fairway Kansas
United States Florida Cancer Specialist - South /ID# 221726 Fort Myers Florida
United States Providence Medical Foundation /ID# 241646 Fullerton California
United States Hackensack Univ Med Ctr /ID# 221654 Hackensack New Jersey
United States University of Texas MD Anderson Cancer Center /ID# 217994 Houston Texas
United States Indiana Blood & Marrow Transpl /ID# 221586 Indianapolis Indiana
United States MidAmerica Division, Inc. /ID# 221743 Kansas City Missouri
United States Thompson Cancer Survival Ctr /ID# 231689 Knoxville Tennessee
United States Moores Cancer Center at UC San Diego /ID# 218012 La Jolla California
United States Northwell Health - Monter Cancer Center /ID# 222996 Lake Success New York
United States Rocky Mountain Cancer Centers, LLP- Littleton /ID# 222562 Littleton Colorado
United States Weill Cornell Medical College /ID# 220933 New York New York
United States Mid Illinois Hematology & Oncology Associates, Ltd /ID# 224204 Normal Illinois
United States UPMC Hillman Cancer Ctr /ID# 218134 Pittsburgh Pennsylvania
United States Florida Cancer Specialists - North /ID# 221727 Saint Petersburg Florida
United States University of Utah /ID# 221009 Salt Lake City Utah
United States Utah Cancer Specialists Salt Lake Clinic /ID# 221961 Salt Lake City Utah
United States VA Puget Sound Health Care System /ID# 231691 Seattle Washington
United States Highlands Oncology Group, PA /ID# 221824 Springdale Arkansas
United States Texas Oncology - Northeast Texas /ID# 241813 Tyler Texas
United States Florida Cancer Specialists - East /ID# 221728 West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Bulgaria,  Canada,  Croatia,  France,  Germany,  Greece,  Israel,  Italy,  Japan,  Korea, Republic of,  Netherlands,  New Zealand,  Russian Federation,  Serbia,  South Africa,  Spain,  Sweden,  Taiwan,  Turkey,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24) Reduction in spleen volume is measured by magnetic resonance imaging (MRI) or computed tomography (CT), per International Working Group (IWG) criteria. At Week 24
Secondary Change in Total Symptom Score (TSS) Reduction in TSS is measured by Myelofibrosis Symptom Assessment Form (MFSAF) v4.0. Baseline (Week 0) Up to Week 24
Secondary Percentage of Participants who achieve Spleen Volume Reduction of at least 35% (SVR35) Reduction in spleen volume is measured by MRI or CT, per IWG criteria. Baseline (Week 0) Up to Week 96
Secondary Duration of 35% Spleen Volume Reduction (SVR35) Duration of SVR35 is defined as the time between the date of first response of spleen volume reduction of 35% achievement to the date of the first assessment where the spleen volume is less than 35% reduction from baseline and is at least 25% increase from the nadir (the lowest spleen volume). Baseline (Week 0) Up to Week 96
Secondary Change In Fatigue Change in fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue SF 7a. Baseline (Week 0) Up to Week 24
Secondary Change in Physical Functioning Change in physical functioning is measured by the physical functioning domain of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 or death. Baseline (Week 0) Up to Week 24
Secondary Percentage of Participants who achieve Anemia Response The rate of anemia response will be assessed according to current International Working Group-Myeloproliferative Neoplasms Research and European LeukemiaNet (IWG-MRT/ELN) criteria. Baseline (Week 0) Up to Week 96
Secondary Overall Survival (OS) OS is defined as the time from the date of randomization to the date of death from any cause. Up To approximately 8 Years
Secondary Leukemia-Free Survival Leukemia-free survival is defined as the number of days from the date of randomization to the onset date of documented leukemia, disease progression due to leukemia, or death due to leukemia, whichever occurs first. Up To approximately 8 Years
Secondary Percentage of Participants who Achieve Reduction in Grade of Bone Marrow Fibrosis Change in grade of bone marrow fibrosis will be measured per the European consensus grading system through bone marrow biopsy. Baseline (Week 0) Up to Week 96
See also
  Status Clinical Trial Phase
Suspended NCT01211691 - Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) Phase 1/Phase 2
Active, not recruiting NCT03222609 - A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Phase 2
Active, not recruiting NCT04454658 - Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis Phase 1
Completed NCT01816256 - Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms N/A
Terminated NCT04480086 - Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis Phase 1
Completed NCT01224496 - Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders Phase 1/Phase 2
Active, not recruiting NCT04468984 - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis Phase 3

External Links